{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T16:05:50Z","timestamp":1779465950568,"version":"3.53.1"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This study aimed to evaluate the value of the OMGRate and MG-QOL 15 in assessing quality of life (QoL) before and after treatment in ocular myasthenia gravis (OMG) and to validate the applicability of OMGRate in the Chinese OMG population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective observational cohort study was conducted via questionnaire among patients diagnosed with OMG at our hospital between November 2022 and January 2024. Patient outcomes were assessed at pre-treatment (baseline), 1, 3, and 6\u202fmonths post-treatment. Efficacy was assessed using the OMGRate and O-QMGS, while the MG-QOL15 was used to evaluate the QoL of OMG patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Our study included 52 patients with OMG. Age of onset and first Symptoms significantly impacted patients\u2019 QoL (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001); AChR-Ab positivity and thymic abnormalities were associated with disease severity (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.05). Longitudinal observations revealed significant reductions in all scale scores (OMGRate, MG-QOL15, O-QMGS), reaching optimal levels at 6\u202fmonths. OMGRate-e and OMGRate-q scores demonstrated moderate to strong positive correlations across all observation times; OMGRate and OMGRate-q scores showed positive correlations with MG-QOL15 scores at all observation time points; OMGRate and OMGRate-e scores showed positive correlations with O-QMGS scores only at post-treatment observation time points.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The OMGRate was validated as an effective method for severity assessment in Chinese OMG patients. OMG significantly impairs patients\u2019 QoL, whereas standardised treatment not only effectively alleviates clinical symptoms but also concurrently improves quality of life, revealing good consistency between symptomatic improvement and patient-reported outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2026.1842388","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T15:26:43Z","timestamp":1779463603000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Validation and clinical utility of OMGRate and MG-QOL15 in evaluating symptoms and quality of life in Chinese patients with ocular myasthenia gravis"],"prefix":"10.3389","volume":"17","author":[{"given":"Ting","family":"Tang","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, The First Affiliated Hospital of Jinan University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiwen","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The First Affiliated Hospital of Jinan University","place":["Guangzhou, China"]},{"name":"Department of Ophthalmology, Dongguan Binhaiwan Central Hospital","place":["Dongguan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youran","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The First Affiliated Hospital of Jinan University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuying","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The First Affiliated Hospital of Jinan University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The First Affiliated Hospital of Jinan University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rijia","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The First Affiliated Hospital of Jinan University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The First Affiliated Hospital of Jinan University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/s1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1080\/08164622.2022.2029683","article-title":"Ocular myasthenia gravis: a review and practical guide for clinicians","volume":"105","author":"Shuey","year":"2022","journal-title":"Clin Exp Optom"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/wco.0000000000000775","article-title":"Ocular myasthenia gravis: updates on an elusive target","volume":"33","author":"Melson","year":"2020","journal-title":"Curr Opin Neurol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"721","DOI":"10.3760\/cma.j.cn113694-20250120-00041","article-title":"Chinese guideline for diagnosis and treatment of myasthenia gravis (2025 edition)","volume":"58","author":"Shi","year":"2025","journal-title":"Chin J Neurol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3969\/j.issn.1006-2963.2021.01.001","article-title":"Chinese guidelines for the diagnosis and treatment of myasthenia gravis(2020 version)","volume":"28","author":"Chang","year":"2021","journal-title":"Chin J Neuroimmunol Neurol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.ncl.2018.01.003","article-title":"Ocular myasthenia","volume":"36","author":"Al-Haidar","year":"2018","journal-title":"Neurol Clin"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"e1594","DOI":"10.1212\/wnl.0000000000207642","article-title":"Clinical characteristics associated with secondary generalization in patients with ocular myasthenia gravis: a systematic review and Meta-analysis","volume":"101","author":"Fang","year":"2023","journal-title":"Neurology"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/mus.26719","article-title":"Severity and depression can impact quality of life in patients with myasthenia gravis","volume":"61","author":"Alanazy","year":"2020","journal-title":"Muscle Nerve"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1212\/WNL.0b013e3181dc1b1e","article-title":"The MG composite: a valid and reliable outcome measure for myasthenia gravis","volume":"74","author":"Burns","year":"2010","journal-title":"Neurology"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1080\/01658107.2019.1660686","article-title":"Preliminary findings of a dedicated ocular myasthenia gravis rating scale: the OMGRate","volume":"44","author":"Wong","year":"2020","journal-title":"Neuroophthalmology"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e210150","DOI":"10.1212\/wnl.0000000000210150","article-title":"Multicenter validation of the ocular myasthenia gravis rating scale questionnaire","volume":"104","author":"Wong","year":"2025","journal-title":"Neurology"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/mus.21609","article-title":"Construct and concurrent validation of the MG-QOL15 in the practice setting","volume":"41","author":"Burns","year":"2010","journal-title":"Muscle Nerve"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/mus.21883","article-title":"The MG-QOL15 for following the health-related quality of life of patients with myasthenia gravis","volume":"43","author":"Burns","year":"2011","journal-title":"Muscle Nerve"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/mus.26313","article-title":"Translation, cross-cultural adaptation, and validation of the chinese version of the 15-item myasthenia gravis quality of life questionnaire","volume":"59","author":"Miao","year":"2019","journal-title":"Muscle Nerve"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/j.1749-6632.1998.tb11015.x","article-title":"Reliability testing of the quantitative myasthenia gravis score","volume":"841","author":"Barohn","year":"1998","journal-title":"Ann N Y Acad Sci"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1365-2753.2010.01434.x","article-title":"Translation, adaptation and validation of instruments or scales for use in cross-cultural health care research: a clear and user-friendly guideline","volume":"17","author":"Sousa","year":"2011","journal-title":"J Eval Clin Pract"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/j.1524-4733.2005.04054.x","article-title":"Principles of good practice for the translation and cultural adaptation process for patient-reported outcomes (PRO) measures: report of the ISPOR task force for translation and cultural adaptation","volume":"8","author":"Wild","year":"2005","journal-title":"Value Health"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"6521","DOI":"10.1177\/1756286419876521","article-title":"Do early prednisolone and other immunosuppressant therapies prevent generalization in ocular myasthenia gravis in Western populations: a systematic review and meta-analysis","volume":"12","author":"Li","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3389\/fneur.2018.00077","article-title":"Clinical characteristics of juvenile myasthenia gravis in southern China","volume":"9","author":"Huang","year":"2018","journal-title":"Front Neurol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/ane.13549","article-title":"Comorbidities in older patients with myasthenia gravis\u2014comparison between early and late-onset disease","volume":"145","author":"Klimiec-Moskal","year":"2022","journal-title":"Acta Neurol Scand"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"470","DOI":"10.5498\/wjp.v12.i3.470","article-title":"Studying the relationship between clinical features and mental health among late-onset myasthenia gravis patients","volume":"12","author":"Yu","year":"2022","journal-title":"World J Psychiatry"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/00207454.2017.1344237","article-title":"Factors affecting outcome in ocular myasthenia gravis","volume":"128","author":"Mazzoli","year":"2018","journal-title":"Int J Neurosci"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1002\/mus.25983","article-title":"Low conversion rate of ocular to generalized myasthenia gravis in Singapore","volume":"57","author":"Teo","year":"2018","journal-title":"Muscle Nerve"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ajo.2019.04.017","article-title":"Incidence, epidemiology, and transformation of ocular myasthenia gravis: a population-based study","volume":"205","author":"Hendricks","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s42466-023-00252-w","article-title":"The impact of thymectomy in subgroups of myasthenia gravis patients: a single center longitudinal observation","volume":"5","author":"Menghesha","year":"2023","journal-title":"Neurol Res Pract"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"108","DOI":"10.22599\/bioj.315","article-title":"The role of Thymoma and Thymic hyperplasia as prognostic risk factors for secondary generalisation in adults with ocular myasthenia gravis: a systematic narrative review","volume":"19","author":"Wilson","year":"2023","journal-title":"Br Ir Orthopt J"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1212\/01.Wnl.0000163988.28892.79","article-title":"Quantitative myasthenia gravis score: assessment of responsiveness and longitudinal validity","volume":"64","author":"Bedlack","year":"2005","journal-title":"Neurology"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3233\/jnd-150082","article-title":"Psychometric properties of the quantitative myasthenia gravis score and the myasthenia gravis composite scale","volume":"2","author":"Barnett","year":"2015","journal-title":"J Neuromuscul Dis"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1212\/wnl.0000000000207278","article-title":"Addressing outcome measure variability in myasthenia gravis clinical trials","volume":"101","author":"Guptill","year":"2023","journal-title":"Neurology"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1842388\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T15:26:47Z","timestamp":1779463607000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1842388\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":30,"alternative-id":["10.3389\/fneur.2026.1842388"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1842388","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"article-number":"1842388"}}